Cocrystal Pharma Doses First Subjects in Groundbreaking Phase 1b Study of CDI-988 for Norovirus Prevention and Treatment

Key Highlights

• First subjects dosed in Phase 1b clinical trial evaluating CDI-988, a direct-acting oral antiviral for norovirus, at Emory University School of Medicine.
• CDI-988 is the first oral antiviral drug candidate specifically developed for norovirus acute gastroenteritis.
• No approved treatments or vaccines are currently available for norovirus, a virus with a global economic burden of \$60 billion annually.
• The study aims to assess CDI-988’s efficacy and safety as both a preventive and treatment measure for norovirus infections.
• Positive clinical progress could significantly impact the company’s valuation and future prospects.

Detailed Report

Cocrystal Pharma, Inc. (Nasdaq: COCP) has announced a significant milestone with the dosing of the first subjects in its Phase 1b human challenge study (NCT07198139) of CDI-988, an oral antiviral being developed for the prevention and treatment of norovirus infections. This trial is a critical step for the company in addressing a major unmet medical need in the antiviral market, as norovirus remains a leading cause of viral gastroenteritis worldwide with no approved therapeutics or vaccines available.

Study Design and Objectives

The Phase 1b clinical trial is a randomized, double-blind, placebo-controlled study being conducted at the Emory University School of Medicine. The study intends to enroll up to 40 healthy adults, aged 18–49. All participants in the trial will be deliberately infected with the GII.2 (Snow Mountain Virus) strain of norovirus, which is known for its high infectivity and is one of the most prevalent circulating strains.

Key features of the study include:

• The initial cohort will determine the infectivity rate of the challenge inoculum, GII.2 norovirus.
• Subsequent cohorts will be administered CDI-988 or placebo to assess its efficacy as both a preventive and treatment intervention.
• The primary endpoint is the reduction in the incidence of clinical symptoms versus placebo.
• Secondary endpoints include reductions in viral shedding, disease severity, and comprehensive safety and pharmacokinetic profiling.

About CDI-988 and Its Market Potential

CDI-988 is designed to inhibit a highly conserved region of the viral 3CL protease present in all known norovirus strains, including the predominant GII.2, GII.4, and emerging GII.17 variants. This makes CDI-988 a promising candidate for broad-spectrum efficacy against multiple norovirus genotypes, potentially positioning Cocrystal for a first-to-market advantage in a high-burden therapeutic area.

The company highlights CDI-988’s potential value in high-risk settings such as hospitals, nursing homes, cruise ships, schools, and military facilities—environments where norovirus outbreaks can be especially disruptive and costly.

Strong Preclinical and Regulatory Progress

CDI-988 has already demonstrated favorable safety and tolerability in a prior Phase 1 study, with dosing up to 1200 mg (the highest dose planned for the current Phase 1b trial). The program has received a “Study May Proceed” letter from the FDA (September 2025) and Institutional Review Board approval from Emory University (December 2025).

Norovirus: An Unmet Global Medical Need

Norovirus causes approximately 685 million cases globally each year, with a \$60 billion economic impact. In the United States alone, it accounts for an estimated 21 million infections, 109,000 hospitalizations, 465,000 emergency department visits, and 900 deaths annually. In developing countries, the burden is even greater, leading to up to 1.1 million hospitalizations and 218,000 deaths among children yearly. The lack of approved treatments or vaccines makes the need for new therapeutics acute and urgent.

Proprietary Drug Discovery Platform

Cocrystal Pharma employs a proprietary structure-based drug discovery platform that utilizes advanced structural biology, enzymology, and medicinal chemistry. This technology enables rapid and precise drug design by providing near-atomic resolution structures of inhibitor complexes, accelerating the identification of novel binding sites and structure-activity relationships. This efficiency may allow Cocrystal to progress its pipeline more quickly and cost-effectively than competitors.

Potential Price-Sensitive and Shareholder-Relevant Factors

• This is the first clinical trial of a direct-acting antiviral specifically targeting norovirus, a major step toward addressing a significant market gap.
• Positive results from this proof-of-concept study could serve as a major catalyst for the company’s valuation and open the path to later-stage clinical development, potential partnerships, or licensing opportunities.
• Any adverse findings or delays in the clinical study, or failure to meet endpoints, could negatively impact share value.
• The company is exposed to standard clinical, regulatory, and operational risks, including potential supply chain disruptions, partner financial difficulties, and the emergence of resistant viral strains or competing therapeutics.

Management Commentary

Dr. Sam Lee, President and co-CEO of Cocrystal Pharma, commented: “Commencement of this study is a significant milestone for Cocrystal and a critical step toward addressing a serious global unmet medical need, given the debilitating symptoms and high societal cost of norovirus outbreaks. CDI-988 has particular potential in high-risk environments such as hospitals, nursing homes, cruise ships, schools, and military facilities. The human challenge model is designed to provide proof-of-concept for our compound in a tightly controlled setting.”

He further noted the scientific significance of this trial as the first involving a direct-acting antiviral specifically targeting norovirus infections, and expressed optimism that the efficacy and safety data could validate the company’s drug discovery platform.

Conclusion

The initiation of this first-in-human Phase 1b trial of CDI-988 for norovirus represents a potentially transformative development for Cocrystal Pharma and its shareholders. With no current treatments or vaccines for a virus that causes significant morbidity, mortality, and economic burden worldwide, the trial’s progress and results will be closely watched by investors, industry partners, and public health stakeholders. Any positive efficacy or safety data from this study could have a rapid and material impact on the company’s market position and share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consider all relevant risks and uncertainties, including those outlined in Cocrystal Pharma’s filings with the SEC, before making any investment decisions. The company’s forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. No obligation is undertaken to update any forward-looking statements.

View Cocrystal Pharma, Inc. Historical chart here